Protagonist Therapeutics, Inc.
ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES

Last updated:

Abstract:

Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Status:
Application
Type:

Utility

Filling date:

28 Jan 2021

Issue date:

25 Nov 2021